Diabetes in France: The Markets for Monitoring, Insulin, Oral Hypoglycemics, and Drugs to Treat Complications

Diabetes monitoring and therapeutics to manage the disease and its complications continues to be an attractive market for many manufacturers. However, the factors that affect the potential of diabetes markets—including population demographics and the attitude of healthcare policy makers and clinicians—can seem like shifting sands from one country to the next. That’s why Kalorama is now offering affordable country-specific profiles on the diabetes markets that provide you with the facts you need to implement your strategy in each of the top world markets.

For each country, these profiles provide prevalence information on type 1 and type 2 diabetes; market size and growth for diabetes monitoring, insulin, and oral hypoglycemics; and market estimates for drugs to treat complications in the diabetic population, including hypertension, dyslipidemia, arrhythmias, and peripheral vascular disease. Information about market dynamics and country-specific policy and cultural issues are also provided when they can shed light on the particularities of the national marketplace.